Mutual regulation of TGF-β1, TβRII and ErbB receptors expression in human thyroid carcinomas

Experimental Cell Research

Volumn 327, Issue 1, 2014, Pages 24-36

  Mincione, Gabriella ^a   Tarantelli, Chiara ^a   Vianale, Giovina ^a   Di Marcantonio, Maria Carmela ^a   Cotellese, Roberto ^a,b   Francomano, Franco ^b   Di Nicola, Marta ^a   Costantini, Erica ^a   Cichella, Annadomenica ^b   Muraro, Raffaella ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Policlinico SS Annunziata   (Italy)

Author keywords

EGF; ErbB receptors; Human thyroid carcinoma; TGF 1; T RII

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THYROID CANCER CELL LINE; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; WESTERN BLOTTING;

EGF; ERBB RECEPTORS; HUMAN THYROID CARCINOMA; TGF-Β1; TΒRII;

ADULT; AGED; CADHERINS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84906935533     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.06.012     Document Type: Article

References (73)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. J. Am. Med. Assoc. 2006, 295:2164-2167.
3. Kato S., Kobayashi T., Yamada K., Nishii K., Sawada H., Ishiguro H., Itoh M., Funahashi H., Nagasaka A. Expression of erbB receptors mRNA in thyroid tissues. Biochem. Biophys. Acta 2004, 1673:194-200.
4. Schiff B.A., McMurphy A.B., Jasser S.A., Younes M.N., Doan D., Yigitbasi O.G., Kim S., Zhou G., Mandal M., Bekele B.N., Holsinger F.C., Sherman S.I., Yeung S.C., El-Naggar A.K., Myers J.N. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin. Cancer Res. 2004, 10:8594-8602.
5. Nicolussi A., D'Inzeo S., Santulli M., Colletta G., Coppa A. TGF-β control of rat thyroid follicular cells differentiation. Mol. Cell Endocrinol. 2003, 207:1-11.
6. Pisarev M.A., Thomasz L., Juvenal G.J. Role of transforming growth factor beta in the regulation of thyroid function and growth. Thyroid 2009, 19:881-892.
7. Uttamsingh S., Bao X., Nguyen K.T. Synergistic effect between EGF and TGF-β1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 2008, 27:2626-2634.
8. Wendt M.K., Smith J.A., Schiemann W.P. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010, 29:6485-6498.
9. Asmis L.M., Gerber H., Kaempf J., Studer H. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J. Endocrinol. 1995, 145:513-520.
10. Aasland R., Akslen L.A., Varhaug J.E., Lillehaug J.R. Co-expression of the genes encoding transforming growth factor-α and its receptor in papillary carcinomas of the thyroid. Int. J. Cancer 2006, 46:382-387.
11. Hoelting T., Siperstein A.E., Clark O.H., Duh Q.-Y. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 1994, 79:401-408.
12. van der Laan B.F., Freeman J.L., Asa S.L. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 1995, 5:67-73.
13. Bechtner G., Schopohl D., Rafferzeder M., Gärtner R., Welsch U. Stimulation of thyroid cell proliferation by epidermal growth factor is different from cell growth induced by thyrotropin or insulin-like growth factor I. Eur. J. Endocrinol. 1996, 134:639-648.
14. Mizukami Y., Nonomura A., Hashimoto T., Michigishi T., Noguchi M., Matsubara F., Yanaihara N. Immunohistochemical demonstration of epidermal growth factor and c-myc oncogene product in normal, benign and malignant thyroid tissues. Histopathology 1991, 18:11-18.
15. Colletta G., Cirafici A.M., Di Carlo A. Dual effect of transforming growth factor β on rat thyroid cells: inhibition of thyrotropin-induced proliferation and reduction of thyroid-specific differentiation markers. Cancer Res. 1989, 49:3457-3462.
16. Carneiro C., Alvarez C.V., Zalvide J., Vidal A., Domínguez F. TGF-beta1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growth. Oncogene 1998, 16:1455-1465.
17. Depoortere F., Pirson I., Bartek J., Dumont J.E., Roger P.P. Transforming growth factor β1 selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27kip1. Mol. Biol. Cell 2000, 11:1061-1076.
18. Padua D., Massagué J. Roles of TGFbeta in metastasis. Cell Res. 2009, 19:89-102.
19. del Castillo G., Murillo M.M., Alvarez-Barrientos A., Bertran E., Fernández M., Sánchez A., Fabregat I. Autocrine production of TGF-β confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: role of EGF receptor ligands. Exp. Cell Res. 2006, 312:2860-2871.
20. Murillo M.M., del Castillo G., Sánchez A., Fernández M., Fabregat I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-β1 in hepatocytes. Oncogene 2005, 24:4580-4587.
21. Hoffmann S., Gläser S., Wunderlich A., Lingelbach S., Dietrich C., Burchert A., Muller H., Rothmund M., Zielke A. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors-a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbeck's Arch. Surg. 2006, 391:589-596.
22. Hölting T., Zielke A., Siperstein A.E., Clark O.H., Duh Q.-Y. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 1994, 79:806-813.
23. Nilsson M., Dahlman T., Westermark B., Westermark K. Transforming growth factor-β promotes epidermal growth factor-induced thyroid cell migration and follicle neoformation in collagen gel separable from cell proliferation. Exp. Cell Res. 1995, 220:257-265.
24. Gebäck T., Schulz M.M.P., Koumoutsakos P., Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. BioTechniques 2009, 46:265-274.
25. Stupack D.G., Cho S.Y., Klemke R.L. Molecular signaling mechanisms of cell migration and invasion. Immunol. Res. 2000, 21:83-88.
26. Hartsough M.T., Mulder K.M. Transforming growth factor β activation of p44mapk in proliferating cultures of epithelial cells. J. Biol. Chem. 1995, 270:7117-7124.
27. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
28. Akslen L.A., Varhaug J.E. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995, 76:1643-1654.
29. Wiseman S.M., Griffith O.L., Melck A., Masoudi H., Gown A., Nabi I.R., Jones S.J.M. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions. Am. J. Surg. 2008, 195:667-673.
30. Weng L.-P., Brown J.L., Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and-independent pathways. Hum. Mol. Genet. 2001, 10:237-242.
31. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
32. Wiseman S.M., Griffith O.L., Deen S., Rajput A., Masoudi H., Gilks B., Goldstein L., Gown A., Jones S.J.M. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch. Surg. 2007, 142:717-729.
33. Bierie B., Moses H.L. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
34. De Caestecker M.P., Parks W.T., Frank C.J., Castagnino P., Bottaro D.P., Roberts A.B., Lechleider R.J. Smad2 transduces common signals from receptor serinethreonine and tyrosine kinases. Genes Dev. 1998, 12:1587-1592.
35. Kretzschmar M., Doody J., Massagué J. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nat. Cell Biol. 1997, 389:618-622.
36. Kretzschmar M., Doody J., Timokhina I., Massagué J. A mechanism of repression of TGFβ/ Smad signaling by oncogenic Ras. Genes Dev. 1999, 13:804-816.
37. Mincione G., Cirafici M., Lazzereschi D., Pepe S., Ciardiello F., Colletta G. Loss of thyrotropin regulation and transforming growth factor beta-induced growth arrest in erbB-2 overexpressing rat thyroid cells. Cancer Res. 1993, 53:5548-5553.
38. Song K., Krebs T.L., Danielpour D. Novel permissive role of epidermal growth factor in transforming growth factor β (TGF-β) signaling and growth suppression. Mediation by stabilization of TGF-β receptor type II. J. Biol. Chem. 2006, 281:7765-7774.
39. Riesco-Eizaguirre G., Rodríguez I., De La Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69:8317-8325.
40. Knauf J.A., Sartor M.A., Medvedovic M., Lundsmith E., Ryder M., Salzano M., Nikiforov Y.E., Giordano T., Ghossein R.A., Fagin J.A. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 2011, 30:3153-3162.
41. Lo R.S., Wotton D., Massague J. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J. 2001, 20:128-136.
42. Denys H., Derycke L., Hendrix A., Westbroek W., Gheldof A., Narine K., Pauwels P., Gespach C., Bracke M., De Wever O. Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett. 2008, 266:263-274.
43. Xie L., Law B.K., Chytil A.M., Brown K.A., Aakre M.E., Moses H.L. Activation of the Erk Pathway Is Required for TGF-β1-Induced EMT In Vitro1. Neoplasia 2004, 6:603-610.
44. Davies M., Robinson M., Smith E., Huntley S., Prime S., Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-β1 involves MAPK, Smad and AP-1 signalling pathways. J. Biol. Chem. 2005, 95:918-931.
45. Miettinen P.J., Ebner R., Lopez A.R., Derynck R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of Type I Receptors. J. Cell. Biol. 1994, 127:2021-2036.
46. Portella G., Cumming S.A., Liddell J., Cui W., Ireland H., Akhurst R.J., Balmain A. Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differen. 1998, 9:393-404.
47. Bhowmick N.A., Zent R., Ghiassi M., McDonnell M., Moses H.L. Integrin β1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity. J. Biol. Chem. 2001, 276:46707-46713.
48. Wakefield L.M., Roberts A.B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 2002, 12:22-29.
49. Fujimoto K., Sheng H., Shao J., Beauchamp R.D. Transforming Growth Factor-β1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Exp. Cell Res. 2001, 266:239-249.
50. Ellenrieder V., Hendler S.F., Boeck W., Seufferlein T., Menke A., Ruhland C., Adler G., Gress T.M. Transforming Growth Factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001, 61:4222.
51. Grünert S., Jechlinger M., Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003, 4:657-665.
52. Gan Y., Shi C., Inge L., Hibner M., Balducci J., Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010, 29:4947-4958.
53. Saji M., Ringel M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol. Cell Endocrinol. 2010, 321:20-28.
54. Shaw L.M., Rabinovitz I., Wang H.H., Toker A., Mercurio A.M. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 1997, 91:949-960.
55. Park B.K., Zeng X., Glazer R.I. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res. 2001, 61:7647-7653.
56. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., Danino M., Karlan B.Y., Slamon D.J. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003, 63:196-206.
57. Hutchinson J.N., Jin J., Cardiff R.D., Woodgett J.R., Muller W.J. Activation of Akt-1 (PKB-α) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004, 64:3171-3178.
58. Irie H.Y., Pearline R.V., Grueneberg D., Hsia M., Ravichandran P., Kothari N., Natesan S., Brugge J.S. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 2005, 171:1023-1034.
59. Seton-Rogers S.E., Lu Y., Hines L.M., Koundinya M., LaBaer J., Muthuswamy S.K., Brugge J.S. Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1257-1262.
60. Zavadil J., Bitzer M., Liang D., Yang Y.C., Massimi A., Kneitz S., Piek E., Bottinger E. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6686-6691.
61. Mulder K.M. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev. 2000, 11:23-35.
62. Finlay G.A., Thannickal V.J., Fanburg B.L., Paulson K.E., Factor-β1-induced Transforming Growth Activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor. J. Biochem. Chem. 2000, 275:27650-27656.
63. Andersen P., Pedersen M.W., Woetmann A., Villingsh M., Stockhausen M.-T., Ødum N., Poulsen H.S. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int. J. Cancer 2008, 122:342-349.
64. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., Wang Y., Trink A., El-Naggar A.K., Tallini G., Vasko V., Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007, 13:1161-1170.
65. Santarpia L., El-Naggar A.K., Cote G.J., Myers J.N., Sherman S.I. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin. Endocrinol. Metab. 2008, 93:278-284.
66. Shinohara M., Chung Y.J., Saji M., Ringel M.D. AKT in thyroid tumorigenesis and progression. Endocrinology 2007, 148:942-947.
67. Ringer M.D., Hayre N., Saito J., Saunier B., Schuppert F., Burch H., Bernet V., Burman K.D., Kohn L.D., Saji M. Overexpression and overactivated of Akt in thyroid carcinoma. Cancer Res. 2001, 61:6105-6111.
68. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 2011, 7:569-580.
69. Tarcic G., Avraham R., Pines G., Amit I., Shay T., Lu Y., Zwang Y., Katz M., Ben-Chetrit N., Jacob-Hirsch J., Virgilio L., Rechavi G., Mavrothalassitis G., Mills G.B., Domany E., Yarden Y Y. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J. 2012, 26:1582-1592.
70. Lazzereschi D., Ranieri A., Mincione G., Taccogna S., Nardi F., Colletta G. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Cancer Res. 1997, 57:2071-2076.
71. Grände M., Franzen Å., Karlsson J.-O., Ericson L.E., Heldin N.-E., Nilsson M. Transforming growth factor-β and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. Cell Sci. 2002, 115:4227-4236.
72. Docherty N.G., O'Sullivan O.E., Healy D.A., Murphy M., O'Neill A.J., Fitzpatrick J.M., Watson R.W.G. The TGF-β1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation,. Am. J. Physiol.: Ren. Physiol. 2005, 290:1202-1212.
73. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., Pereira A.M., Romijn J.A., Smit J.W. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2006, 91:313-319.